Davy Research

Venn Life Sciences (VENN.L, VENN LN)

  • 3.6
  • 60.3
  • 69.4

Company Profile

Venn is a European CRO focussed on providing pre-clinical and clinical trial services to pharma, biotech and medtech clients. A CRO manages clinical trials on behalf of healthcare clients. It can assist in clinical trial site selection, investigator and patient recruitment, study design, trials management, data management and analysis, and regulatory affairs. Consultancy and technology services around these functions can also be provided. Since it listed in late 2012, Venn has focussed on the expansion of its revenue base, its range of services and its geographic reach. This has been achieved via organic growth but predominantly through the acquisition of small European CROs for cash, equity or a combination of both.


Major Shareholders%
Livingbridge 21.7
Calculus Capital Ltd8.5
Groen Kees4.9
  • VENN LIFE SCIENCES

    Closing Price (p): 5.9

  • RATING 07/06/16

  • PREVIOUS RATING

Analyst(S)

COMPANY DATA

UPCOMING EVENTS

  • There are no upcomming events at present